Phathom Pharmaceuticals, Inc. (PHAT) News
Track canonical SquawkNews coverage tagged to PHAT, Phathom Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Phathom Pharmaceuticals to participate in upcoming investor conferences
Phathom Pharmaceuticals said members of its management team are scheduled to participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
PHAT - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHAT - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:00 PM UTC
L
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est
Phathom Pharmaceuticals (NASDAQ: PHAT ) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
EARNINGS | Jul 30, 2026, 11:01 AM UTC
L
PHAT - Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
PHAT - Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 10:59 AM UTC